Bioceres Crop Solutions (NASDAQ:BIOX) Issues Quarterly Earnings Results

Bioceres Crop Solutions (NASDAQ:BIOX) issued its quarterly earnings results on Monday. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.44), Zacks reports. Bioceres Crop Solutions had a negative return on equity of 33.97% and a negative net margin of 92.85%.

Bioceres Crop Solutions Stock Up 2.2%

BIOX traded up $0.01 on Monday, hitting $0.43. The company had a trading volume of 275,527 shares, compared to its average volume of 524,470. The stock has a market capitalization of $27.07 million, a price-to-earnings ratio of -0.11 and a beta of 0.44. Bioceres Crop Solutions has a 12-month low of $0.30 and a 12-month high of $2.19. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.70 and a current ratio of 0.88. The stock has a fifty day moving average price of $0.38 and a 200-day moving average price of $0.44.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded Bioceres Crop Solutions from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, July 13th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Bioceres Crop Solutions currently has an average rating of “Reduce” and a consensus target price of $2.00.

About Bioceres Crop Solutions

Bioceres Crop Solutions Corp. is an agricultural biotechnology company focused on developing, manufacturing and commercializing a range of crop inputs designed to enhance yields and improve sustainability. The company’s portfolio includes biological seed treatments, inoculants for nitrogen fixation, specialty fertilizers and proprietary biopesticides, which are formulated to support plant health and resilience under varying environmental conditions.

Among its flagship offerings is the HB4 drought-tolerant wheat technology, the first genetically modified wheat developed to withstand water stress, which has received regulatory approval in several markets.